Continuation of Covered Calls Position in Halozyme Therapeutics Inc.

The Covered Calls Advisor Portfolio has a Covered Calls position in Halozyme Therapeutics Inc. (ticker HALO) which expired last Friday with the stock at $67.35 which was below the $70.00 strike price.  Today this position was continued by rolling out to the January 16th, 2026 monthly options expiration date at the same $70.00 strike price by selling-to-open two Calls at $1.45 per share when the price of Halozyme's stock was $68.57.  

As detailed below, a potential outcome for this Halozyme Therapeutics investment if the stock is in-the-money and therefore assigned on the options expiration date is +4.6% absolute return-on-investment over 49 days (equivalent to +34.0% annualized-return-on-investment) if the stock closes above the $70.00 strike price on the 1/16/2026 options expiration date.   The details showing this potential return-on-investment result are as follows:  

Halozyme Therapeutics Inc. (HALO) -- Continuation of Covered Calls Position

The net debit buy/write limit order was executed as follows:

11/28/2025 Bought 200 shares of Halozyme Therapeutics stock @ $71.57 per share.  
11/28/2025 Sold 2 HALO December 19th, 2025 $70.00 Call options @ $3.25 per share.  Note: the Implied Volatility of the Calls was 32.5 when this position was established.  
12/19/2025 Two HALO Calls expired out-of-the-money, so 200 Halozyme Therapeutics shares remain in the Covered Calls Advisor Portfolio

12/26/2025 Continued this Covered Calls position by selling-to-open two Halozyme January 16th, 2026 $70.00 Call options at $1.45 per share.  The Implied Volatility of these Calls was 38.5 when they were sold.

A possible overall performance results (including commissions) if the position is in-the-money on the options expiration date is as follows:
Halozyme Covered Calls Net Investment: $13,665.34
= ($71.57 - $3.25) * 200 shares + $1.34 commission

Net Profit Components:
(a) Options Income: +$937.32
= ($3.25 + $1.45) * 200 shares - $2.68 commissions
(b) Dividend Income: +$0.00
(c) Capital Appreciation (If Halozyme stock is above the $70.00 strike price at the January 16th options expiration date): -$314.00
= ($70.00 strike price - $71.57 stock purchase price) * 200 shares

Potential Total Net Profit (If stock price is in-the-money and therefore assigned at the Jan. 16th, 2026 options expiration date): +$623.32
= (+$937.32 options income + $0.00 dividend income - $314.00 capital appreciation)

Potential Absolute Return-on-Investment (If stock price is in-the-money and therefore assigned on the 1/16/2026 options expiration date): +4.6% = +$623.32/$13,665.34

Potential Equivalent Annualized-Return-on-Investment: +34.0%
= (+$623.32/$13,665.34) * (365/49 days)